Abstract |
Benazepril is a nonsulfhydryl ACE inhibitor with favorable pharmacodynamic and pharmacokinetic properties, well-established antihypertensive effects and a good tolerability profile. Recent clinical studies have demonstrated that patients treated with benazepril alone or in combination with hydrochlorothiazide or amlodipine may achieve beneficial renal outcomes that extend beyond blood pressure control. Furthermore, the recent Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed decreased cardiovascular morbidity and mortality with benazepril when administered as a cotreatment. An additional novel therapeutic area for benazepril is atrial fibrillation. Differences between combination therapies have implications for which patients may be best suited to particular interventions, and further studies are required to fully ascertain this potential.
|
Authors | Vivencio Barrios, Carlos Escobar |
Journal | Expert review of cardiovascular therapy
(Expert Rev Cardiovasc Ther)
Vol. 8
Issue 12
Pg. 1653-71
(Dec 2010)
ISSN: 1744-8344 [Electronic] England |
PMID | 21108548
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adrenergic beta-Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
- Benzazepines
- Calcium Channel Blockers
- Diuretics
- Prodrugs
- benazeprilat
- benazepril
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Angiotensin-Converting Enzyme Inhibitors
(adverse effects, pharmacokinetics, therapeutic use)
- Antihypertensive Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Atrial Fibrillation
(drug therapy)
- Benzazepines
(adverse effects, pharmacokinetics, therapeutic use)
- Calcium Channel Blockers
(therapeutic use)
- Diuretics
(therapeutic use)
- Drug Therapy, Combination
- Humans
- Hypertension
(drug therapy)
- Kidney
(drug effects)
- Practice Guidelines as Topic
- Prodrugs
(adverse effects, pharmacokinetics, therapeutic use)
- Societies, Medical
|